Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Claudia Lundgren, Cecilia Ahlin, Lars Holmberg, Rose-Marie Amini, Marie-Louise Fjällskog & Carl Blomqvist. (2015) Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study. Acta Oncologica 54:4, pages 543-549.
Read now
Read now
Malcolm D. Mattes, Justin M. Mann, Hani Ashamalla & Ajay Tejwani. (2013) Routine Histopathologic Characteristics Can Predict Oncotype DXTM Recurrence Score in Subsets of Breast Cancer Patients. Cancer Investigation 31:9, pages 604-606.
Read now
Read now
Marit Synnestvedt, Elin Borgen, Hege G. Russnes, Neena T. Kumar, Ellen Schlichting, Karl-Erik Giercksky, Rolf Kåresen, Jahn M. Nesland & Bjørn Naume. (2013) Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncologica 52:1, pages 91-101.
Read now
Read now
Articles from other publishers (39)
Anas Mohamed, Linnea T. Olsson & Joseph Geradts. (2023) Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index. Breast Cancer Research and Treatment 201:3, pages 447-460.
Crossref
Crossref
Ran Song, Dong-Eun Lee, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, Jai Hong Han, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Youngmee Kwon, Jaeyeon Woo & So-Youn Jung. (2023) Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer. Cancers 15:18, pages 4451.
Crossref
Crossref
Anas Mohamed, Aisha Kousar, Jan Wong, Nasreen Vohra, Mahvish Muzaffar & Joseph Geradts. (2022) Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. Archives of Pathology & Laboratory Medicine 146:10, pages 1258-1267.
Crossref
Crossref
Hongxiao Li, Jigang Wang, Zaibo Li, Melad Dababneh, Fusheng Wang, Peng Zhao, Geoffrey H. Smith, George Teodoro, Meijie Li, Jun Kong & Xiaoxian Li. (2022) Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score. Frontiers in Medicine 9.
Crossref
Crossref
Brandon S. Nichols, Erika Chelales, Roujia Wang, Amanda Schulman, Jennifer Gallagher, Rachel A. Greenup, Joseph Geradts, Josephine Harter, Paul K. Marcom, Lee G. Wilke & Nirmala Ramanujam. (2020) Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. Journal of Biophotonics 13:10.
Crossref
Crossref
Rohit Bhargava, Beth Z. Clark, Gloria J. Carter, Adam M. Brufsky & David J. Dabbs. (2020) The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer. Modern Pathology 33:8, pages 1563-1570.
Crossref
Crossref
Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim & Seock-Ah Im. (2020) Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer. Clinical Breast Cancer 20:2, pages 98-107.e1.
Crossref
Crossref
Amila Orucevic, John L. Bell, Megan King, Alison P. McNabb & Robert E. Heidel. (2019) Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. The Breast 46, pages 116-125.
Crossref
Crossref
Rohit Bhargava, Beth Z Clark & David J Dabbs. (2019) Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing. American Journal of Clinical Pathology 151:3, pages 316-323.
Crossref
Crossref
Isaac Kim, Hee Jun Choi, Jai Min Ryu, Se Kyung Lee, Jong Han Yu, Seok Won Kim, Seok Jin Nam & Jeong Eon Lee. (2019) A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning. European Journal of Surgical Oncology 45:2, pages 134-140.
Crossref
Crossref
David J Dabbs, Beth Z Clark, Kate Serdy, Agnieszka Onisko, Adam M Brufsky, Sherie Smalley, Stephen Perkins & Rohit Bhargava. (2018)
Pathologist's health-care value in the triage of Oncotype DX
®
testing: a value-based pathology study of tumour biology with outcomes
. Histopathology 73:4, pages 692-700.
Crossref
Crossref
Kamaljeet Singh, Xin He, Elizabeth T. Kalife, Shahrzad Ehdaivand, Yihong Wang & C. James Sung. (2017) Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Research and Treatment 168:1, pages 29-34.
Crossref
Crossref
HarshimaDisvini Wijesinghe, Poobalasingham Thuvarakan, Anandi Samarasekera & MenakaDilani S. Lokuhetty. (2018) Prognostic indices predictive of short-term disease-free survival of breast carcinoma patients receiving primary surgical treatment in Sri Lanka. Indian Journal of Pathology and Microbiology 61:4, pages 505.
Crossref
Crossref
Amila Orucevic, John L. Bell, Alison P. McNabb & Robert E. Heidel. (2017) Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Research and Treatment 163:1, pages 51-61.
Crossref
Crossref
Giancarlo Pruneri & Francesca Boggio. 2017. Breast Cancer. Breast Cancer
121
131
.
Hyun-seok KimChristopher B. UmbrichtPeter B. IlleiAshley Cimino-MathewsSoonweng ChoNivedita ChowdhuryMaria Cristina Figueroa-MagalhaesCatherine PesceStacie C. JeterCharles MylanderMartin RosmanLorraine TafraBradley M. TurnerDavid G. HicksTyler A. JensenDylan V. MillerDeborah K. ArmstrongRoisin M. ConnollyJohn H. FettingRobert S. MillerBen Ho ParkVered StearnsKala VisvanathanAntonio C. WolffLeslie Cope. (2016) Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology 34:36, pages 4390-4397.
Crossref
Crossref
David G. Hicks & Susan C. Lester. 2016. Diagnostic Pathology: Breast. Diagnostic Pathology: Breast
386
393
.
Philip E. BomeislCheryl L. Thompson, Lyndsay N. Harris & Hannah L. Gilmore. (2015) Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma. Archives of Pathology & Laboratory Medicine 139:12, pages 1546-1549.
Crossref
Crossref
Michele M. Gage, Martin Rosman, W. Charles Mylander, Erica Giblin, Hyun-seok Kim, Leslie Cope, Christopher Umbricht, Antonio C. Wolff & Lorraine Tafra. (2015) A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence?Score Assay. Clinical Breast Cancer 15:6, pages 467-472.
Crossref
Crossref
Vanda Farahmand Torous & Sophia K Apple. (2015) Did Oncotype DX® Recurrence Score Accurately Predict the Risk of Recurrence in Breast Cancer? A 10 Year Period Study in a Single Institution. Open Medicine Journal 2:1, pages 37-42.
Crossref
Crossref
Moo Hyun Lee, Wonshik Han, Jeong Eon Lee, Ku Sang Kim, Heeseung Park, Jongjin Kim, Soo Youn Bae, Hyun Joo Shin, Jong Won Lee & Eun Sook Lee. (2014) The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea. Cancer Research and Treatment 47:2, pages 208-214.
Crossref
Crossref
Xianxiao Zhou, Bailiang Li, Yuannv Zhang, Yunyan Gu, Beibei Chen, Tongwei Shi, Lu Ao, Pengfei Li, Shan Li, Chunyang Liu & Zheng Guo. (2013) A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. Breast Cancer Research and Treatment 142:3, pages 505-514.
Crossref
Crossref
Abigail Silva, Garth H. Rauscher, Kent Hoskins, Ruta Rao & Carol Estwing Ferrans. (2013) Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines. Breast Cancer Research and Treatment 142:3, pages 667-672.
Crossref
Crossref
Helen Ingoldsby, Mark Webber, Deirdre Wall, Carl Scarrott, John Newell & Grace Callagy. (2013) Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. The Breast 22:5, pages 879-886.
Crossref
Crossref
Meghan Milburn, Martin Rosman, Charles Mylander & Lorraine Tafra. (2013)
Is Onco
type
DX Recurrence Score (RS) of Prognostic Value Once HER2-Positive and. Low-ER Expression Patients are Removed?
. The Breast Journal 19:4, pages 357-364.
Crossref
Crossref
Julianne R. Biroschak, Gordon F. Schwartz, Juan P. Palazzo, Adam D. Toll, Kristin L. Brill, Rebecca J. Jaslow & Sun Yong Lee. (2013) Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation. The Breast Journal 19:3, pages 269-275.
Crossref
Crossref
Molly E Klein, David J Dabbs, Yongli Shuai, Adam M Brufsky, Rachel Jankowitz, Shannon L Puhalla & Rohit Bhargava. (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Modern Pathology 26:5, pages 658-664.
Crossref
Crossref
Gary H. Lyman, Jay Baker, Joseph Geradts, Janet Horton, Gretchen Kimmick, Jeffrey Peppercorn, Scott Pruitt, Randall P. Scheri & E. Shelley Hwang. (2013) Multidisciplinary Care of Patients with Early-Stage Breast Cancer. Surgical Oncology Clinics of North America 22:2, pages 299-317.
Crossref
Crossref
Zsuzsanna Varga, Peter Sinn, Florian Fritzsche, Arthur von Hochstetter, Aurelia Noske, Peter Schraml, Christoph Tausch, Andreas Trojan & Holger Moch. (2013) Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. PLoS ONE 8:3, pages e58483.
Crossref
Crossref
Qingchao Qiu, Pengcheng Lu, Yuzhu Xiang, Yu Shyr, Xi Chen, Brian David Lehmann, Daniel Joseph Viox, Alfred L. George & Yajun Yi. (2013) A Data Similarity-Based Strategy for Meta-analysis of Transcriptional Profiles in Cancer. PLoS ONE 8:1, pages e54979.
Crossref
Crossref
Elena Brachtel. (2012) Molecular Pathology of the Breast. Surgical Pathology Clinics 5:4, pages 793-819.
Crossref
Crossref
Somaira Nowsheen, Khaled Aziz, Mihalis I. Panayiotidis & Alexandros G. Georgakilas. (2012) Molecular markers for cancer prognosis and treatment: Have we struck gold?. Cancer Letters 327:1-2, pages 142-152.
Crossref
Crossref
Blazej Zbytek, Cynthia Cohen, Jason Wang, Andrew Page, Daron J. Williams & Amy L. Adams. (2012) Nottingham-defined Mitotic Score. Applied Immunohistochemistry & Molecular Morphology, pages 1.
Crossref
Crossref
Geza Acs, Nicole N Esposito, John Kiluk, Loretta Loftus & Christine Laronga. (2012) A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Modern Pathology 25:4, pages 556-566.
Crossref
Crossref
K. H. Allison, P. L. Kandalaft, C. M. Sitlani, S. M. Dintzis & A. M. Gown. (2011) Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Research and Treatment 131:2, pages 413-424.
Crossref
Crossref
Shelly S. Lo & Kathy S. Albain. (2011) Impact of Multigene Assays in Early Stage Breast Cancer. The Oncologist 16:11, pages 1482-1483.
Crossref
Crossref
Jennifer E. Joh, Nicole N. EspositoJohn V. Kiluk, Christine Laronga, M. Catherine Lee, Loretta Loftus, Hatem Soliman, Judy C. Boughey, Carol ReynoldsThomas J. LawtonPeter I. AcsLucio GordanGeza Acs. (2011) The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor–Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists. The Oncologist 16:11, pages 1520-1526.
Crossref
Crossref
Soonmyung Paik. (2011) Is gene array testing to be considered routine now?. The Breast 20, pages S87-S91.
Crossref
Crossref
Dara L Aisner & Dan Theodorescu. (2011) Genetic testing for metastasis: potential for improved cancer treatment. Future Oncology 7:6, pages 697-701.
Crossref
Crossref